BERLIN—MD1003, a high-dose pharmaceutical grade biotin, is effective in the treatment of patients with progressive multiple sclerosis (MS...
BERLIN—Cognitive impairment in patients with multiple sclerosis (MS) can vary in presence and degree in a manner that is...
BERLIN—Switching from interferon beta-1a to ocrelizumab after two years at the start of the OPERA I and OPERA II open-...
BERLIN—Relapse-induced escalation to a highly effective disease-modifying therapy (DMT) is associated with a reduced...
BERLIN—Levels of neurofilament light chain (NfL) indicate that patients with secondary progressive multiple sclerosis (...
BERLIN—Smoking and low vitamin D levels are key modifiable prognostic factors that show a dramatic interaction with risk...
BERLIN – The monoclonal antibody satralizumab reduced by 62% relapses of neuromyelitis optica spectrum disorder over 24 weeks, as compared with...
BERLIN – Future brain atrophy and 3-month confirmed disability worsening could be predicted from change in baseline levels of the potential MS...
BERLIN – Spinal cord volume tracked with disability level in patients with a mismatch between disability status and intracerebral lesion load.
BERLIN—Dimethyl fumarate and teriflunomide have similar efficacy in terms of risk of relapse and worsening of Expanded...
BERLIN—Widespread focal cortical damage at multiple sclerosis (MS) onset identifies patients likely to have frequent...
BERLIN—Data from the Big Multiple Sclerosis Data (BMSD) Network indicate that the optimal time to start disease-...
BERLIN – Disease-modifying treatment for relapsing-remitting multiple sclerosis decreased the risk of disability progression at 12 months by 28...
BERLIN—Research supports the previously observed association of periventricular lesions with cortical thinning in...
BERLIN—Crude all-cause mortality rates among patients with multiple sclerosis (MS) who were treated with rituximab were...
BERLIN—Serum neurofilament light chain (sNfL) levels are clinically relevant, and data suggest cut points to enable...
BERLIN – Men with MS and either depression or bipolar disorder were at especially higher risk of worsening disability.
